

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/EP05/002447

International filing date: 08 March 2005 (08.03.2005)

Document type: Certified copy of priority document

Document details: Country/Office: GB
Number: 0405289.0
Filing date: 09 March 2004 (09.03.2004)

Date of receipt at the International Bureau: 30 March 2005 (30.03.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse




The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.


In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed *Andrew Cug*

Dated 23 December 2004





1/77
10MAR04 EB79532-1 000245
P01/7700 0.00-0405289.0 ACCOUNT CHA

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office
Cardiff Road
Newport
South Wales NP10 8QQ

4-33595P1

1. Your reference

2. Patent application number
(The Patent Office will fill in this part)

0405289.0

- 9 MAR 2004

3. Full name, address and postcode of the or
of each applicant
(underline all surnames)

NOVARTIS AG
LICHTSTRASSE 35
4056 BASEL
SWITZERLAND

7125487005
SWITZERLAND

Patent ADP number (*if you know it*)If the applicant is a corporate body, give
the country/state of its incorporation

4. Title of invention

Organic Compounds

5. Name of your agent (*If you have one*)
"Address for service" in the United
Kingdom to which all correspondence
should be sent
(including the postcode)

Craig McLean
Novartis Pharmaceuticals UK Limited
Patents and Trademarks
Wimblehurst Road
Horsham, West Sussex
RH12 5AB

Patents ADP number (*if you know it*)

Country	Priority application number <i>(if you know it)</i>	Date of filing (day/month/year)
---------	--	------------------------------------

6. If you are declaring priority from one or
more earlier patent applications, give
the country and the date of filing of the
or of each of these earlier applications
and (*if you know it*) the or each application
number

Number of earlier application	Date of filing (day/month/year)
----------------------------------	------------------------------------

7. If this application is divided or otherwise
derived from an earlier UK
application, give the number and the
filing date of the earlier application8. Is a statement of inventorship and of
right to grant of a patent required in
support of this request? (Answer 'Yes' if:

Yes

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is not named as an applicant, or
 - c) any named applicant is a corporate body.
- (see note (d))*

Patents Form 1/77

AND THOUSAND EIGHTH EDITION 1999

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 16 *(Handwritten mark)*

Claim(s) 2 *(Handwritten mark)*

Abstract

Drawing(s)

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

1 *(Handwritten mark)*

Request for substantive examination (*Patents Form 10/77*)

Any other documents
(please specify)

11.

I/We request the grant of a patent on the basis of this application

Signature

Date



Craig McLean

9th March 2004

12. Name and daytime telephone number of person to contact in the United Kingdom

Mrs. Silke Schnerr

(01403) 323069

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes


- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0845 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) Once you have filled in the form you must remember to sign and date it.
- e) For details of the fee and ways to pay, please contact the Patent Office.

- 1 -

Organic Compounds


The present invention relates to beta-amino acid derivatives, process for their production, their uses and pharmaceutical compositions containing them.

More particularly, the invention provides a compound of formula I




wherein


- R₁ is C₁₋₆alkyl optionally substituted by OH, C₁₋₂alkoxy or 1 to 6 fluorine atoms; C₂₋₆alkenyl; or C₂₋₆alkynyl;
- R₂ is a radical of formula a, b or c



a



b



c

wherein

- R₆ is C₁₋₁₂alkyl optionally substituted by halogen, by an optionally substituted cycloalkyl, by an optionally substituted phenyl, by an optionally substituted heteroaryl, or by an optionally substituted heterocyclic residue,
wherein the C₁₋₁₂alkyl optionally is interrupted by one or more O or C=O; and
wherein the phenyl, heteroaryl, cycloalkyl, and/or heterocyclic residue may be substituted by 1 to 5 substituents selected from hydroxy; halogen; C₁₋₄alkyl; C₁₋₄alkyl substituted by 1 to 5 fluorine atoms; C₁₋₄alkoxy; C₁₋₄alkoxy substituted by 1 to 5 fluorine atoms; cyano; phenyl; and phenyl substituted by 1 to 5 substituents selected from hydroxy, halogen, C₁₋₄alkyl, C₁₋₄alkyl substituted by 1 to 5 fluorine atoms, C₁₋₄alkoxy, C₁₋₄alkoxy substituted by 1 to 5 fluorine atoms, and cyano;
- R₇ is H, optionally substituted phenyl, optionally substituted heteroaryl, wherein the phenyl and/or heteroaryl independently may be substituted by 1 to 5 substituents selected from hydroxy; halogen; C₁₋₄alkyl; C₁₋₄alkyl substituted by 1 to 5 fluorine atoms; C₁₋₄alkoxy; C₁₋₄alkoxy substituted by 1 to 5 fluorine atoms; and cyano;
- X is O, C=O, S or a bond;
- Z is N or CH;

- 2 -

R_3 is $-A-B-COOH$ wherein each of A and B, independently is a bond, C=O or CDE, wherein each of D and E, independently is H, halogen, C_{1-3} alkyl, OH; with the proviso that A and B are not both C=O; and each of R_4 and R_5 , independently, is H, C_{1-4} alkyl optionally substituted by 1, 2 or 3 halogen atoms, or acyl;

in free form or in salt form.

Alkyl or alkyl moiety may be straight or branched chain, e.g. methyl, ethyl, propyl, iso-propyl or butyl. Alkenyl may be e.g. vinyl. Alkynyl may be e.g. propyn-2-yl. Cycloalkyl may be e.g. C_{3-6} cycloalkyl.

Acyl may be a residue W-CO wherein W is C_{1-6} alkyl, C_{3-6} cycloalkyl, phenyl or phenyl C_{1-4} alkyl.


Halogen may be F, Cl or Br, preferably F or Cl.

Heteroaryl may be a 5 to 8 membered aromatic ring comprising 1 to 4 heteroatoms selected from N, O and S, e.g. pyridyl, pyrimidinyl, pyrazinyl, furyl, oxazolyl, isoxazolyl, thiophenyl, thiazolyl, isothiazolyl, pyrrolyl, imidazolyl, or pyrazolyl.

By heterocyclic residue is meant a 3 to 8, preferably 5 to 8, membered saturated or unsaturated heterocyclic ring comprising e.g. tetrahydrofuryl, tetrahydropyran, aziridinyl, piperidinyl, pyrrolidinyl, piperazinyl.

Compounds of formula I may exist in free form or in salt form, e.g. addition salts with e.g. inorganic acids, such as hydrochloride, hydrobromide or sulfate, salts with organic acids, such as acetate, fumarate, maleate, benzoate, citrate, malate, methanesulfonate or benzenesulfonate salts; the carboxylate group may also be present in salt form, e.g. an ammonium salt or salts with metals such as sodium, potassium, calcium, zinc or magnesium, or a mixture thereof. Compounds of formula I and their salts, in hydrate or solvate form are also part of the invention.

When the compounds of formula I have asymmetric centers in the molecule, various optical isomers are obtained. The present invention also encompasses enantiomers, racemates, diastereoisomers and mixtures thereof. For example, the central carbon atom bearing R_1 , R_3 and NR_4R_5 may have the R or S configuration. Compounds having the following 3-dimensional configuration are generally preferred:




Moreover, when the compounds of formula I include geometric isomers, the present invention embraces cis-compounds, trans-compounds and mixtures thereof. Similar considerations apply in relation to starting materials exhibiting asymmetric carbon atoms or unsaturated bonds as mentioned above, e.g. compounds of formula II, III or IV as indicated below.

In the compounds of formula I, the following significances are preferred individually or in any sub-combination:

1. R_1 is CH_3 or CH_2-OH ;
2. R_3 is CH_2-COOH ;
3. each of R_4 and R_5 is hydrogen;
4. R_7 is hydrogen, phenyl or thiophenyl;
5. X is O or bond; and
6. if R_2 is a radical of formula a, XR_6 is para to $-(CH_2)_2-CR_1R_3(NR_4R_5)$.

The present invention also includes a process for the preparation of a compound of formula I which process comprises removing the protecting group present in a compound of formula II




wherein R_1 , R_2 and R_5 are as defined above, R'_3 is $-A-B-COOR_8$ wherein A and B are as defined above and R_8 is a hydrolysable or hydrogenolysable group and R'_4 is an amino protecting group,

and, where required, converting the compounds of formula I obtained in free form into the desired salt form, or vice versa.


Removal of the protecting group may be carried out in accordance with methods known in the art. The removal of the amino protecting groups may conveniently be performed according to methods known in the art, e.g. by hydrolysis, e.g. in an acidic medium, for example using hydrochloric acid. Examples of protecting groups for amino groups are e.g. as disclosed in "Protective Groups in Organic Synthesis" T.W. Greene, J.Wiley & Sons NY, 2nd ed., chapter 7, 1991, and references therein, e.g. benzyl, p-methoxybenzyl, methoxy-

methyl, tetrahydropyranyl, trialkylsilyl, acyl, tert.-butoxy-carbonyl, benzyloxycarbonyl, 9-fluorenyl methoxy carbonyl, trifluoroacetyl, and the like.


The present invention also includes a process for the preparation of a compound of formula II, wherein X is O, which process comprises alkylating a compound of formula III



wherein R_1 , R'_3 , R'_4 and R_5 are as defined above, and R_2 is a radical of formula a', or b'



a'




b'

to introduce the desired residue R_6 .

Alkylation of the compounds of formula III may be performed according to methods known in the art, e.g. by nucleophilic substitution, e.g. by reaction with an alkylating agent R_6X_3 wherein X_3 is mesylate, tosylate, triflate, nosylate or an halogen, e.g. chloride, bromide or iodide. The alkylation may also be carried out by following the Mitsunobu protocol (e.g. as disclosed in Hughes, Organic Preparations and Procedures International 28, 127-64, 1996 or D.L. Hughes, Org. React. 42, 335, 1992), in solution or on solid phase support synthesis, e.g. by attaching the compound of formula III to a resin. Alternatively, either triphenylphosphine or e.g. diethyl azocarboxylate bound to a resin, e.g. polystyrene, can be used.

The present invention also includes a process for the preparation of a compound of formula I which process comprises hydrolyzing the cyano group present in a compound of formula IV




wherein R_1 , R_2 and R_5 are as defined above, R'_3 is $-\text{A}-\text{B}-\text{CN}$ and R'_4 is an amino protecting group, and, where required, converting the compounds of formula I obtained in free form into the desired salt form, or vice versa.

Insofar as the production of the starting materials is not particularly described, the compounds are known or may be prepared analogously to methods known in the art or as disclosed in the Examples hereinbefore.

The following Examples are illustrative of the invention. Melting points are uncorrected.

RT	=	room temperature
DMF	=	dimethylformamide
HPLC	=	high performance liquid chromatography
DMSO	=	dimethylsulfoxide
THF	=	tetrahydrofuran
AcOEt	=	ethyl acetate


Example 1: (R)-3-Amino-5-(4-heptyloxy-phenyl)-3-methyl-pentanoic acid



In a microwave vessel, a stirred solution of [(R)-1-cyanomethyl-3-(4-heptyloxy-phenyl)-1-methyl-propyl]-carbamic acid tert-butyl ester (136 mg, 0.34 mMol) in dioxane (2 ml) is treated with HCl (37% aqueous solution, 1 ml). The mixture is heated to 160 °C for 1.3 hours. The reaction mixture is then cooled to RT and concentrated under reduced pressure. Preparative HPLC eluting with 5%→95% acetonitril in H₂O (+ 0.1% trifluoro acetic acid) gives the title compound as an amorphous white powder.

¹H-NMR (d6-DMSO): 7.95 (br s, 1H), 7.06 (d, J = 9 Hz, 2H), 6.83 (d, J = 9 Hz, 2H), 3.89 (t, J = 7 Hz, 2H), 3.40-3.20 (m, 2H), 2.53-2.45 (m, 2H), 1.86-1.75 (m, 2H), 1.66 (q, J = 8 Hz, 2H), 1.41-1.20 (m, 11H), 0.85 (t, J = 7 Hz, 3H). MS (ESI+): m/z = 322.1 [M+H]⁺

Preparation of [(R)-1-Cyanomethyl-3-(4-heptyloxy-phenyl)-1-methyl-propyl]-carbamic acid tert-butyl ester




To a stirred solution of (R)-4-[2-(4-heptyloxy-phenyl)-ethyl]-4-methyl-2,2-dioxo-2λ*6*- [1,2,3]oxathiazolidine-3-carboxylic acid tert-butyl ester (174 mg, 0.40 mMol) in DMF (5 ml) is added sodium cyanide (94 mg, 1.91 mMol). The mixture is stirred at RT for 25 hours. Additional sodium cyanide (37 mg, 0.76 mMol) is added and the mixture is stirred at RT for

- 6 -

18 hours. The reaction mixture is then poured onto a biphasic mixture of AcOEt and NaHCO₃ (saturated aqueous solution). The aqueous phase is extracted twice with AcOEt. The combined organic layers are dried (Na₂SO₄) and concentrated under reduced pressure. Column chromatography eluting with 5% AcOEt in toluene gives the title compound as a colourless oil.

¹H-NMR (CDCl₃): 7.09-7.04 (m, 2H), 6.83-6.78 (m, 2H), 4.59 (br s, 1H), 3.91 (t, J = 7 Hz, 2H), 3.08 (br d, J = 7 Hz, 1H), 2.78 (d, J = 7 Hz, 1H), 2.59-2.50 (m, 2H), 2.32-2.20 (m, 1H), 1.82-1.70 (m, 3H), 1.48 (s, 9H), 1.48-1.18 (m, 11H), 0.90 (t, J = 7 Hz, 3H). MS (ESI+): m/z = 468.3 [M+CH₃CN+Na]⁺, 827.6 [2M+Na]⁺.


Preparation of (R)-4-[2-(4-Heptyloxy-phenyl)-ethyl]-4-methyl-2,2-dioxo-2λ⁶-[1,2,3]oxathiazolidine-3-carboxylic acid tert-butyl ester



To a stirred solution of (R)-4-[2-(4-heptyloxy-phenyl)-ethyl]-4-methyl-2-oxo-[1,2,3]oxathiazolidine-3-carboxylic acid tert-butyl ester (275 mg, 0.63 mMol) in acetonitril/H₂O (9/1, 10 ml) is added sodium periodate (401 mg, 1.88 mMol) and ruthenium(III) chloride (13 mg, 0.06 mMol). The mixture is stirred at RT for 18 hours. Additional ruthenium(III) chloride (65 mg, 0.30 mMol) is added and the mixture is stirred at RT for 65 hours. The reaction mixture is then filtered over a pad of celite, and the filtrate is poured onto a biphasic mixture of AcOEt and Na₂S₂O₃ (saturated aqueous solution). The aqueous phase is extracted three times with AcOEt. The combined organic layers are dried (Na₂SO₄) and concentrated under reduced pressure. Column chromatography eluting with 5%→15% AcOEt in heptane gives the title compound a colourless oil.

¹H-NMR (CDCl₃): 7.07 (d, J = 8 Hz, 2H), 6.81 (d, J = 8 Hz, 2H), 4.42 (d, J = 9 Hz, 1H), 4.16 (d, J = 9 Hz, 1H), 3.92 (t, J = 6 Hz, 2H), 2.67-2.50 (m, 2H), 2.43-2.32 (m, 1H), 2.09-1.95 (m, 1H), 1.75 (qt, J = 7 Hz, 2H), 1.62 (s, 3H), 1.53 (s, 9H), 1.50-1.22 (m, 8H), 0.90 (t, J = 7 Hz, 3H). MS (ESI+): m/z = 478.2 [M+Na]⁺, 933.4 [2M+Na]⁺.

Preparation of (R)-4-[2-(4-Heptyloxy-phenyl)-ethyl]-4-methyl-2-oxo-[1,2,3]oxathiazolidine-3-carboxylic acid tert-butyl ester




A stirred solution of thionyl chloride (0.14 ml, 1.91 mMol) in acetonitril (10 ml) is cooled to -40 °C. At this temperature, a solution of [(R)-3-(4-heptyloxy-phenyl)-1-hydroxymethyl-1-methyl-propyl]-carbamic acid tert-butyl ester (300 mg, 0.76 mMol) in acetonitril (5 ml), and pyridine (0.31 ml, 3.81 mMol) are added successively. The mixture is allowed to warm to -10 °C over 2.5 hours. The reaction mixture is then poured onto a biphasic mixture of AcOEt and HCl (aqueous, 1 M). The aqueous phase is extracted twice with AcOEt. The combined organic layers are washed with NaHCO₃ (saturated aqueous solution), dried (Na₂SO₄) and concentrated under reduced pressure. Column chromatography eluting with 5%→15% AcOEt in heptane gives the title compounds as colourless oils (2 diastereomers, dr = 1:1).

Diastereomer 1: ¹H-NMR (CDCl₃): 7.07 (d, J = 9 Hz, 2H), 6.81 (d, J = 9 Hz, 2H), 4.95 (br d, J = 9 Hz, 1H), 4.28 (d, J = 9 Hz, 1H), 3.92 (t, J = 6 Hz, 2H), 2.62 (dt, J = 5 Hz, 8 Hz, 1H), 2.50 (dt, J = 5 Hz, 8 Hz, 1H), 2.40-2.28 (m, 1H), 2.10-1.99 (m, 1H), 1.76 (qt, J = 7 Hz, 2H), 1.66-1.23 (m, 20H), 0.90 (t, J = 7 Hz, 3H). MS (ESI+): m/z = 462.3 [M+Na]⁺, 901.6 [2M+Na]⁺.

Diastereomer 2: ¹H-NMR (CDCl₃): 7.04 (d, J = 8 Hz, 2H), 6.80 (d, J = 8 Hz, 2H), 4.82 (br d, J = 9 Hz, 1H), 4.59 (d, J = 9 Hz, 1H), 3.91 (t, J = 7Hz, 2H), 2.59 (dt, J = 5 Hz, 8 Hz, 1H), 2.39 (dt, J = 5 Hz, 7 Hz, 1H), 2.28-2.16 (m, 1H), 1.93-1.82 (m, 1H), 1.80-1.22 (m, 22H), 0.90 (t, J = 7 Hz, 3H). MS (ESI+): m/z = 462.3 [M+Na]⁺, 901.6 [2M+Na]⁺.

Preparation of [(R)-3-(4-Heptyloxy-phenyl)-1-hydroxymethyl-1-methyl-propyl]-carbamic acid tert-butyl ester




To a stirred solution of [(R)-1-hydroxymethyl-3-(4-hydroxy-phenyl)-1-methyl-propyl]-carbamic acid tert-butyl ester (2.06 g, 6.98 mMol) in ethanol (100 ml) is added potassium carbonate (2.90 g, 20.8 mMol) and methanesulfonic acid heptyl ester (2.04 g, 10.5 mMol). The mixture

is heated to reflux temperature and stirred at that temperature for 6 hours. The mixture is then cooled to RT and stirred at RT overnight. The reaction mixture is then poured onto a biphasic mixture of AcOEt and HCl (aqueous, 1 M). The aqueous phase is extracted twice with AcOEt. The combined organic layers are washed with NaHCO₃ (saturated aqueous solution), dried (Na₂SO₄) and concentrated under reduced pressure. Column chromatography eluting with 8% AcOEt in toluene gives the title compound as a colourless oil.

¹H-NMR (CDCl₃): 7.10-7.05 (m, 2H), 6.81-6.76 (m, 2H), 4.60 (br s, 1H), 4.07 (br s, 1H), 3.92 (t, J = 6 Hz, 2H), 3.70 (d, J = 12 Hz, 1H), 3.62 (d, J = 12 Hz, 1H), 2.65-2.43 (m, 2H), 2.07-1.94 (m, 1H), 1.88-1.69 (m, 1H), 1.68-1.60 (m, 2H), 1.45 (s, 9H), 1.50-1.25 (m, 8H), 1.22 (s, 3H), 0.88 (t, J = 7 Hz, 3H). MS (ESI+): m/z = 416.1 [M+Na]⁺.


Example 2: (R)-2-Amino-4-(4-heptyloxy-phenyl)-2-methyl-butanoic acid



To a stirred solution of (R)-2-tert-butoxycarbonylamino-4-(4-heptyloxy-phenyl)-2-methylbutyric acid (43 mg, 0.11 mMol) in CH₂Cl₂ (2 ml) is added trifluoroacetic acid (0.1 ml). The mixture is stirred at RT for 8 hours. After that time, the reaction mixture is concentrated under reduced pressure. Column chromatography eluting with 5%→25% MeOH in CH₂Cl₂ gives the title compound as a colourless oil.

¹H-NMR (d6-DMSO): 8.32 (br s, 3H), 7.02 (d, J = 8 Hz, 2H), 6.81 (d, J = 8 Hz, 2H), 3.88 (t, J = 7 Hz, 2H), 2.70-2.58 (m, 1H), 2.42-2.31 (m, 1H), 2.04-1.83 (m, 2H), 1.70-1.62 (m, 2H), 1.45 (s, 3H), 1.44-1.21 (m, 8H), 0.72 (t, J = 7 Hz, 3H). MS (ESI-): m/z = 306.3 [M-H]⁺.

Preparation of (R)-2-tert-Butoxycarbonylamino-4-(4-heptyloxy-phenyl)-2-methyl-butanoic acid




To a stirred solution of [(E)-1-formyl-3-(4-heptyloxy-phenyl)-1-methyl-propyl]-carbamic acid-tert-butyl ester (100 mg, 0.28 mMol) in tert-butanol (1 ml) and 10% aqueous NH₂PO₄ (0.1 ml) added 1 mol % DMSO (0.05 ml). Let stand and column chromatography (10% MeOH in EtOAc).

The mixture is stirred at RT for 1 hour. The reaction mixture is then poured onto a biphasic mixture of AcOEt and HCl (aqueous, 1M). The aqueous phase is extracted twice with AcOEt. The combined organic layers are washed with a small amount of NaHCO₃ (saturated aqueous solution), dried (Na₂SO₄) and concentrated under reduced pressure. Column chromatography eluting with 5% MeOH in CH₂Cl₂ gives the title compound as a colourless oil.

MS (ESI+): m/z = 430.2 [M+Na]⁺.


Preparation of [(R)-1-Formyl-3-(4-heptyloxy-phenyl)-1-methyl-propyl]-carbamic acid tert-butyl ester



To a stirred solution of [(R)-1-hydroxymethyl-3-(4-hydroxy-phenyl)-1-methyl-propyl]-carbamic acid tert-butyl ester (1.98 g, 5.03 mMol) in CH₂Cl₂ (20 ml) is added N-morpholine-N-oxide (884 mg, 7.54 mMol) and tetra-n-propylammonium perruthenate (177 mg, 0.50 mMol). The mixture is stirred at RT for 1 hour. The mixture is then filtered over a short pad of SiO₂ eluting with diethyl ether. The filtrate is concentrated under reduced pressure to give the title compound. The crude product is sufficiently pure to be used in the next stage without further purification.

¹H-NMR (CDCl₃): 9.33 (s, 1H), 7.06-7.01 (m, 2H), 6.82-6.76 (m, 2H), 5.18 (br s, 1H), 3.92 (t, 2H), 2.60-2.49 (m, 1H), 2.44-2.19 (m, 2H), 2.01-1.93 (m, 1H), 1.80-1.71 (m, 2H), 1.55 (s, 3H), 1.48-1.25 (m, 17H), 0.89 (t, J = 7 Hz, 3H). MS (ESI+): m/z = 414.2 [M+Na]⁺.

Example 3: (R)-4-Amino-6-(4-heptyloxy-phenyl)-4-methyl-hexanoic acid




To a stirred solution of (R)-4-tert-butoxycarbonylamino-6-(4-heptyloxy-phenyl)-4-methylhexanoic acid (24 mg, 0.06 mMol) in CH₂Cl₂ (2 ml) is added trifluoroacetic acid (0.1 ml). The mixture is stirred at RT for 6.5 hours. After that time, the reaction mixture is concentrated

- 10 -

under reduced pressure to give the title compound as an amorphous white powder. The crude product is sufficiently pure to be used without further purification.

¹H-NMR (d₆-DMSO): 7.81 (br s, 3H), 7.12-7.07 (m, 2H), 6.85-6.81 (m, 2H), 3.90 (t, J = 7 Hz, 2H), 2.52-2.29 (m, 4H), 1.88-1.80 (m, 2H), 1.77-1.62 (m, 4H), 1.40-1.21 (m, 11H), 0.85 (t, J = 7 Hz, 3H). MS (ESI+): m/z = 336.2 [M+H]⁺.


Preparation of (R)-4-tert-Butoxycarbonylamino-6-(4-heptyloxy-phenyl)-4-methyl-hexanoic acid



To a stirred solution of (E)-(R)-4-tert-butoxycarbonylamino-6-(4-heptyloxy-phenyl)-4-methyl-hex-2-enoic acid (53 mg, 0.12 mMol) in AcOEt (10 ml) is added palladium on charcoal (10 mg, 10%). The reaction is stirred under a H₂-atmosphere at RT for 17 hours. The reaction mixture is filtered over Celite and the filtrate is concentrated under reduced pressure to give the title compound as a colourless oil. The crude product is sufficiently pure to be used in the next stage without further purification.

¹H-NMR (CDCl₃): 7.06 (d, J = 9 Hz, 2H), 6.80 (d, J = 9 Hz, 2H), 4.42 (br s, 1H), 3.92 (t, J = 6 Hz, 2H), 2.51 (t, J = 8 Hz, 2H), 2.38 (t, J = 8 Hz, 2H), 2.28-2.17 (m, 1H), 2.11-2.00 (m, 1H), 1.97-1.70 (m, 4H), 1.50-1.22 (m, 20H), 0.90 (t, J = 7 Hz, 3H). MS (ESI-): m/z = 434.4 [M-H]⁺.

Preparation of (E)-(R)-4-tert-Butoxycarbonylamino-6-(4-heptyloxy-phenyl)-4-methyl-hex-2-enoic acid




To a stirred solution of (E)-(R)-4-tert-butoxycarbonylamino-6-(4-heptyloxy-phenyl)-4-methyl-hex-2-enoic acid ethyl ester (53 mg, 0.12 mMol) in methanol (0.5 ml), THF (0.5 ml) and DMSO (0.5 ml) is added lithium aluminum hydride (1.0 g) and the mixture is stirred at room temperature.

3.5 hours. The reaction mixture is then poured onto a biphasic mixture of AcOEt and HCl (aqueous, 1 M). The aqueous phase is extracted twice with AcOEt. The combined organic layers are washed with a small amount of NaHCO₃ (saturated aqueous solution), dried (Na₂SO₄) and concentrated under reduced pressure to give the title compound. The crude product is sufficiently pure to be used in the next stage without further purification.

¹H-NMR (d6-DMSO): 12.3 (br s, 1H), 7.08-7.00 (m, 2H), 6.91 (br s, 1H), 6.83 (d, J = 16 Hz, 1H), 6.79-6.75 (m, 2H), 5.67 (d, J = 16 Hz, 1H), 3.88 (t, J = 7 Hz, 2H), 2.50-2.31 (m, 1H), 2.00-1.89 (m, 1H), 1.79-1.60 (m, 4H), 1.40-1.19 (m, 20H), 0.83 (t, J = 7 Hz, 3H). MS (ESI+): m/z = 456.3 [M+Na]⁺.

Preparation of (E)-(R)-4-tert-butoxycarbonylamino-6-(4-heptyloxy-phenyl)-4-methyl-hex-2-enoic acid ethyl ester



To a stirred solution of (diethoxy-phosphoryl)-acetic acid ethyl ester (429 mg, 1.92 mMol) in dry THF (7 ml) is added n-butyllithium (0.66 ml, 2.5M in hexane, 1.66 mMol) at -78 °C. The mixture was stirred at -78 °C for 1 hour. After that time, a solution of [(R)-1-formyl-3-(4-heptyloxy-phenyl)-1-methyl-propyl]-carbamic acid tert-butyl ester (500 mg, 1.28 mMol) in THF (4 ml) is added and stirring is continued at -78 °C for 1.5 hours. The mixture is allowed to warm to RT and then stirred at RT for 2 hours. The reaction mixture is then poured onto a biphasic mixture of AcOEt and NaHCO₃ (saturated aqueous solution) and the aqueous phase is extracted twice with AcOEt. The combined organic layers are dried (Na₂SO₄) and concentrated under reduced pressure. Column chromatography eluting with 4% AcOEt in toluene gives the title compound as a colourless oil.

¹H-NMR (CDCl₃): 7.10-7.01 (m, 2H), 7.00 (d, J = 16 Hz, 1H), 6.83-6.78 (m, 2H), 5.86 (d, J = 16 Hz, 1H), 4.60 (br s, 1H), 4.20 (q, J = 7 Hz, 2H), 3.92 (t, J = 7 Hz, 2H), 2.55-2.48 (m, 2H), 2.11-2.01 (m, 1H), 1.99-1.86 (m, 1H), 1.80-1.71 (m, 2H), 1.56 (s, 3H), 1.48-1.22 (m, 20 H), 0.89 (t, J = 7 Hz, 3H).

The compounds of formula I in free form or in pharmaceutically acceptable salt form, exhibit valuable pharmacological properties, e.g. lymphocyte recirculation modulating properties, e.g. as indicated in in vitro and in vivo tests and are therefore indicated for therapy.

A. In vitro

The compounds of formula I have binding affinity to individual human S1P receptors as determined in following assays:

Sphingosine-1-phosphate (S1P) receptor profiling

Agonist activities of compounds are tested on the human S1P receptors EDG-1 (S1P_1), EDG-3 (S1P_3), EDG-5 (S1P_2), EDG-6 (S1P_4) and EDG-8 (S1P_5). Functional receptor activation is assessed by quantifying compound induced GTP [$\gamma^{35}\text{S}$] binding to membrane protein prepared from transfected CHO or RH7777 cells stably expressing the appropriate human S1P receptor. The assay technology used is SPA (scintillation proximity based assay). Briefly, DMSO dissolved compounds are serially diluted and added to SPA- bead (Amersham-Pharmacia) immobilised S1P receptor expressing membrane protein (10-20 $\mu\text{g}/\text{well}$) in the presence of 50 mM Hepes, 100 mM NaCl, 10 mM MgCl₂, 10 μM GDP, 0.1% fat free BSA and 0.2 nM GTP [$\gamma^{35}\text{S}$] (1200 Ci/mmol). After incubation in 96 well microtiterplates at RT for 120 min, unbound GTP [$\gamma^{35}\text{S}$] is separated by a centrifugation step. Luminescence of SPA beads triggered by membrane bound GTP [$\gamma^{35}\text{S}$] is quantified with a TOPcount plate reader (Packard). EC₅₀s are calculated using standard curve fitting software. In this assay, the compounds of formula I have a binding affinity to S1P_1 receptor <50 nM.

Example	S1P_1 EC ₅₀ [nM]	S1P_3 EC ₅₀ [nM]	S1P_4 EC ₅₀ [nM]	S1P_5 EC ₅₀ [nM]
1	11 Agon	209 Agon	117 Agon	203 Agon

Agon = agonist

B. In vivo: Blood Lymphocyte Depletion

A compound of formula I or the vehicle is administered orally by gavage to rats. Tail blood for hematological monitoring is obtained on day -1 to give the baseline individual values, and at 2, 6, 24, 48 and 72 hours after application. In this assay, the compounds of formula I deplete peripheral blood lymphocytes when administered at a dose of 0.03 to 3 mg/kg. For example, following results are obtained: depletion of peripheral blood lymphocytes by more than 30%.

Example 1: 3.2 mg/kg p.o. after 6h

The compounds of formula I are, therefore, useful in the treatment and/or prevention of diseases or disorders mediated by lymphocytes interactions, e.g. in transplantation, such as acute or chronic rejection of cell, tissue or organ allo- or xenografts or delayed graft function, graft versus host disease, autoimmune diseases, e.g. rheumatoid arthritis, systemic lupus erythematosus, hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, diabetes type I or II and the disorders associated therewith, vasculitis, pernicious anemia, Sjoegren syndrome, uveitis, psoriasis, Graves ophthalmopathy, alopecia areata and others, allergic diseases, e.g. allergic asthma, atopic dermatitis, allergic rhinitis/conjunctivitis, allergic contact dermatitis, inflammatory diseases optionally with underlying aberrant reactions, e.g. inflammatory bowel disease, Crohn's disease or ulcerative colitis, intrinsic asthma, inflammatory lung injury, inflammatory liver injury, inflammatory glomerular injury, atherosclerosis, osteoarthritis, irritant contact dermatitis and further eczematous dermatitises, seborrhoeic dermatitis, cutaneous manifestations of immunologically-mediated disorders, inflammatory eye disease, keratoconjunctivitis, myocarditis or hepatitis, ischemia/reperfusion injury, e.g. myocardial infarction, stroke, gut ischemia, renal failure or hemorrhage shock, traumatic shock, angiogenesis, Alzheimer's disease, cancer, e.g. breast cancer, T cell lymphomas or T cell leukemias, infectious diseases, e.g. toxic shock (e.g. superantigen induced), septic shock, adult respiratory distress syndrome or viral infections, e.g. AIDS, viral hepatitis, chronic bacterial infection, or senile dementia. Examples of cell, tissue or solid organ transplants include e.g. pancreatic islets, stem cells, bone marrow, corneal tissue, neuronal tissue, heart, lung, combined heart-lung, kidney, liver, bowel, pancreas, trachea or oesophagus. For the above uses the required dosage will of course vary depending on the mode of administration, the particular condition to be treated and the effect desired.

In general, satisfactory results are indicated to be obtained systemically at daily dosages of from about 0.03 to 2.5 mg/kg per body weight. An indicated daily dosage in the larger mammal, e.g. humans, is in the range from about 0.5 mg to about 100 mg, conveniently administered, for example, in divided doses up to four times a day or in retard form. Suitable unit dosage forms for oral administration comprise from ca. 0.1 to 50 mg active ingredient.

The compounds of formula I may be administered by any conventional route, in particular enterally, e.g. orally, e.g. in the form of tablets or capsules, or parenterally, e.g. in the form of injectable solutions or suspensions, topically, e.g. in the form of lotions, gels, ointments or

creams, or in a nasal or a suppository form. Pharmaceutical compositions comprising a compound of formula I in free form or in pharmaceutically acceptable salt form in association with at least one pharmaceutical acceptable carrier or diluent may be manufactured in conventional manner by mixing with a pharmaceutically acceptable carrier or diluent.

The compounds of formula I may be administered in free form or in pharmaceutically acceptable salt form e.g. as indicated above. Such salts may be prepared in conventional manner and exhibit the same order of activity as the free compounds.

In accordance with the foregoing the present invention further provides:

- 1.1 A method for preventing or treating disorders or diseases mediated by lymphocytes, e.g. such as indicated above, in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof;
- 1.2 A method for preventing or treating acute or chronic transplant rejection or T-cell mediated inflammatory or autoimmune diseases, e.g. as indicated above, in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof;
2. A compound of formula I, in free form or in a pharmaceutically acceptable salt form for use as a pharmaceutical, e.g. in any of the methods as indicated under 1.1 or 1.2 above.
3. A pharmaceutical composition, e.g. for use in any of the methods as in 1.1 or 1.2 above comprising a compound of formula I in free form or pharmaceutically acceptable salt form in association with a pharmaceutically acceptable diluent or carrier therefor.
4. A compound of formula I or a pharmaceutically acceptable salt thereof for use in the preparation of a pharmaceutical composition for use in any of the method as in 1.1 or 1.2 above.

The compounds of formula I may be administered as the sole active ingredient or in conjunction with, e.g. as an adjuvant to, other drugs e.g. immunosuppressive or immunomodulating agents or other anti-inflammatory agents, e.g. for the treatment or prevention of allo- or xenograft acute or chronic rejection or inflammatory or autoimmune disorders; or a chemotherapeutic agent, e.g. a malignant cell anti-proliferative agent. For example, the compounds of formula I may be used in combination with a cytostatic agent.

inhibitor, e.g. cyclosporin A, FK 506 or ISA_{TX}247; a mTOR inhibitor, e.g. rapamycin, 40-O-(2-hydroxyethyl)-rapamycin, CCI779, ABT578, AP23573, AP23464, AP23675, AP23841, TAFA-93, biolimus 7 or biolimus 9; an ascomycin having immunosuppressive properties, e.g. ABT-281, ASM981, etc.; corticosteroids; cyclophosphamide; azathioprene; methotrexate; leflunomide; mizoribine; mycophenolic acid; mycophenolate mofetil; 15-deoxyspergualine or an immunosuppressive homologue, analogue or derivative thereof; immunosuppressive monoclonal antibodies, e.g. monoclonal antibodies to leukocyte receptors, e.g., MHC, CD2, CD3, CD4, CD7, CD8, CD25, CD28, CD40, CD45, CD58, CD80, CD86 or their ligands; other immunomodulatory compounds, e.g. a recombinant binding molecule having at least a portion of the extracellular domain of CTLA4 or a mutant thereof, e.g. an at least extracellular portion of CTLA4 or a mutant thereof joined to a non-CTLA4 protein sequence, e.g. CTLA4Ig (for ex. designated ATCC 68629) or a mutant thereof, e.g. LEA29Y; adhesion molecule inhibitors, e.g. LFA-1 antagonists, ICAM-1 or -3 antagonists, VCAM-4 antagonists or VLA-4 antagonists; or a chemotherapeutic agent, e.g. paclitaxel, gemcitabine, cisplatin, doxorubicin or 5-fluorouracil; or an anti-infectious agent.

Where the compounds of formula I are administered in conjunction with other immunosuppressive / immunomodulatory, anti-inflammatory, chemotherapeutic or anti-infectious therapy, dosages of the co-administered immunosuppressant, immunomodulatory, anti-inflammatory, chemotherapeutic or anti-infectious compound will of course vary depending on the type of co-drug employed, e.g. whether it is a steroid or a calcineurin inhibitor, on the specific drug employed, on the condition being treated and so forth. In accordance with the foregoing the present invention provides in a yet further aspect:

5. A method as defined above comprising co-administration, e.g. concomitantly or in sequence, of a therapeutically effective non-toxic amount of a compound of formula I and at least a second drug substance, e.g. an immunosuppressant, immunomodulatory, anti-inflammatory or chemotherapeutic drug, e.g. as indicated above.
6. A pharmaceutical combination, e.g. a kit, comprising a) a first agent which is a compound of formula I as disclosed herein, in free form or in pharmaceutically acceptable salt form, and b) at least one co-agent, e.g. an immunosuppressant, immunomodulatory, anti-inflammatory, chemotherapeutic or anti-infectious agent. The kit may comprise instructions for its administration.


The terms "co-administration" or "combined administration" or the like as utilized herein are meant to encompass administration of the selected therapeutic agents to a single patient,

and are intended to include treatment regimens in which the agents are not necessarily administered by the same route of administration or at the same time.

The term "pharmaceutical combination" as used herein means a product that results from the mixing or combining of more than one active ingredient and includes both fixed and non-fixed combinations of the active ingredients. The term "fixed combination" means that the active ingredients, e.g. a compound of formula I and a co-agent, are both administered to a patient simultaneously in the form of a single entity or dosage. The term "non-fixed combination" means that the active ingredients, e.g. a compound of formula I and a co-agent, are both administered to a patient as separate entities either simultaneously, concurrently or sequentially with no specific time limits, wherein such administration provides therapeutically effective levels of the 2 compounds in the body of the patient. The latter also applies to cocktail therapy, e.g. the administration of 3 or more active ingredients.

CLAIMS


1. A compound of formula I




wherein

R_1 is C_{1-6} alkyl optionally substituted by OH, C_{1-2} alkoxy or 1 to 6 fluorine atoms; C_{2-6} alkenyl; or C_{2-6} alkynyl;


R_2 is a radical of formula a, b or c



a



b



c

wherein

R_6 is C_{1-12} alkyl optionally substituted by halogen, by an optionally substituted cycloalkyl, by an optionally substituted phenyl, by an optionally substituted heteroaryl, or by an optionally substituted heterocyclic residue,

wherein the C_{1-12} alkyl optionally is interrupted by one or more O or C=O; and

wherein the phenyl, heteroaryl, cycloalkyl, and/or heterocyclic residue may be substituted by 1 to 5 substituents selected from hydroxy; halogen; C_{1-4} alkyl; C_{1-4} alkyl substituted by 1 to 5 fluorine atoms; C_{1-4} alkoxy; C_{1-4} alkoxy substituted by 1 to 5 fluorine atoms; cyano; phenyl; and phenyl substituted by 1 to 5 substituents selected from hydroxy, halogen, C_{1-4} alkyl, C_{1-4} alkoxy, and cyano;

R_7 is H, optionally substituted phenyl, optionally substituted heteroaryl, wherein the phenyl and/or heteroaryl independently may be substituted by 1 to 5 substituents selected from hydroxy; halogen; C_{1-4} alkyl; C_{1-4} alkyl substituted by 1 to 5 fluorine atoms; C_{1-4} alkoxy; C_{1-4} alkoxy substituted by 1 to 5 fluorine atoms; and cyano;

X is O, C=O, S or a bond;


Z is N or O;

R_3 is -A-B-COOH wherein each of A and B, independently is a bond, C=O or CDE, wherein each of D and E, independently is H, halogen, C_{1-3} alkyl, OH; with the proviso that A and B are not both C=O; and


each of R_4 and R_5 , independently, is H, C_{1-4} alkyl optionally substituted by 1, 2 or 3 halogen atoms, or acyl;

in free form or in salt form,
a process for its preparation, its use as a pharmaceutical, a pharmaceutical composition containing such a compound or pharmaceutically acceptable salt thereof, a method of treatment or prevention using such a compound or pharmaceutically acceptable salt thereof, or a pharmaceutical combination comprising such a compound or pharmaceutically acceptable salt thereof, substantially as herein defined and/or described.

2. A compound of formula



wherein R_1 to R_3 and R_5 are as defined in claim 1, and R'_4 is a protecting group, or a salt thereof, and a process for its preparation, substantially as hereinbefore defined and/or described.



4